IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, April 2025
Impact Factor: 7.67

Drug Utilization and Evaluation of Esomeprazole

Gayke Shankar Anil[1], Salgar Omkar Navnath[2], Giram Tushar Bankat[3], Shubhangi Netaji Shindalkar[4], Dr. Prasad Katare[5], Pranit Nagnath Budge[6]
[1,2,3,4,6]Students, Shivlingeshwar College of Pharmacy, Almala, Latur, MH, India
[5]Assistant Professor, , Shivlingeshwar College of Pharmacy, Almala, Latur, MH, India

Abstract: *Esomeprazole, a proton pump inhibitor (PPI), is widely used for the treatment of acid-related gastrointestinal disorders such as GERD, peptic ulcers, and Zollinger-Ellison syndrome. This study aims to evaluate the pattern of drug utilization and assess the rationality of esomeprazole use in a hospital setting. Data was collected retrospectively/prospectively over a period of [insert duration], and parameters such as dosage, duration of therapy, indications, and co-prescribed drugs were analyzed. The findings help identify prescribing trends, adherence to standard treatment guidelines, and opportunities for improving rational use.*

Keywords: Esomeprazole ,Proton Pump Inhibitor (PPI),Drug Utilization Evaluation (DUE) Gastroesophageal Reflux Disease (GERD, Peptic Ulcer Prescribing Patter ,Rational Drug, Tertiary Care Hospital NSAID Prophylaxis

I. INTRODUCTION

Esomeprazole is a proton pump inhibitor (PPI) widely used for the treatment of acid-related gastrointestinal disorders. It is the S-isomer of omeprazole and functions by irreversibly inhibiting the H^+/K^+ ATPase enzyme system in the gastric parietal cells, thereby reducing gastric acid secretion. Esomeprazole is primarily indicated for the management of gastroesophageal reflux disease (GERD), peptic ulcer disease, Zollinger-Ellison syndrome, and for the eradication of *Helicobacter pylori* in combination with antibiotics. It is also used for the prevention of gastric ulcers associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).In recent years, the use of PPIs has increased significantly across various healthcare settings. However, several studies have reported instances of inappropriate or prolonged use of PPIs without clear indications, leading to unnecessary healthcare costs and potential adverse effects such as nutrient malabsorption, increased risk of infections, and kidney disorders.Drug utilization evaluation (DUE) is a vital tool to assess the appropriateness, safety, and cost-effectiveness of drug therapy. It helps in identifying prescribing patterns, assessing adherence to clinical guidelines, and promoting rational drug use.This study aims to evaluate the utilization pattern of esomeprazole in a tertiary care hospital, with a focus on its indications, dosage, duration, route of administration, and co-prescribed medications. The findings of this study will provide insights into the rationality of esomeprazole use and help in optimizing prescribing practices in clinical settings.

II. DRUG PROFILE OF ESOMEPRAZOLE

Esomeprazole is a **proton pump inhibitor (PPI)** used to reduce the amount of acid produced in the stomach. It's the **S-isomer of omeprazole**, which gives it slightly better absorption and effectiveness in some patients.

Key Information:

- **Brand names**: Nexium, Esomac, and others
- **Class**: Proton Pump Inhibitor (PPI)

Mechanism of action:
It irreversibly inhibits the **H^+/K^+ ATPase enzyme (proton pump)** in the gastric parietal cells, preventing the final step of acid secretion.

DOI: 10.48175/IJARSCT-25067

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, April 2025
Impact Factor: 7.67

Uses:

Gastroesophageal reflux disease (GERD)

- **Peptic ulcers** (including NSAID-induced ulcers)
- **Zollinger-Ellison syndrome**
- **Erosive esophagitis**
- **H. pylori eradication** (in combination with antibiotics)

Dosage (common forms):

- **20 mg or 40 mg tablets/capsules** (delayed-release)
- IV form also available for hospital use

Side effects:

- Headache, nausea, diarrhea, constipation
- Long-term use:
- Risk of **vitamin B12 deficiency**
- **Hypomagnesemia**
- **Increased risk of bone fractures**
- **C. difficile infections**

Pharmacokinetic of esomeprazole

1. Absorption

- **Form**: Esomeprazole is administered orally as **enteric-coated delayed-release capsules or tablets** (to prevent degradation in stomach acid).
- **Bioavailability**:
- **~50% after a single 20 mg dose**Increases to **68% after repeated once-daily dosing** (due to reduced first-pass metabolism)
- **Peak plasma concentration (Tmax)**:
- Reached in **1.5 to 2 hours** after oral administration
- **Food interaction**:
- **Delays absorption** and **reduces peak concentration** but **doesn't affect the extent of absorption**

2. Distribution

- **Plasma protein binding**: **~97%**
- **Volume of distribution (Vd)**: **~16 L**

3. Metabolism

- **Hepatic metabolism** primarily via **CYP2C19** (major) and **CYP3A4** (minor)
- Converted to **inactive metabolites**, including:
- **Hydroxyesomeprazole**
- **Desmethyl-esomeprazole**
- **Genetic polymorphism** in **CYP2C19** affects metabolism:
- **Poor metabolizers** have **higher plasma concentrations** and **longer half-life**
- **Extensive metabolizers** clear it faster

4. Excretion

- **Route**: Primarily via **urine (80%)** as inactive metabolites; the rest via **feces**

DOI: 10.48175/IJARSCT-25067

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 3, April 2025 Impact Factor: 7.67

- **Renal excretion of unchanged drug**: Negligible
- **Elimination half-life**:
- ~**1.3 hours** in healthy individuals
- Prolonged in **poor metabolizers**

5. Pharmacodynamic effect

- **Onset of acid suppression**: Within **1 hour**
- **Maximal effect**: After **3–5 days** of regular dosing
- **Duration**: Acid suppression lasts **up to 16–24 hours**

6. Special Populations

- **Hepatic impairment**:
- Moderate to severe impairment (**Child-Pugh Class B or C**) can **increase AUC** (area under the curve)
- **Elderly**: Slightly increased systemic exposure
- **Renal impairment**: No major changes, as metabolism is hepatic

Aim:

To evaluate the therapeutic efficacy, safety, and pharmacokinetic profile of **Esomeprazole** in the treatment of acid-related gastrointestinal disorders.

Objectives:

- To understand the mechanism of action of Esomeprazole as a proton pump inhibitor (PPI).
- To evaluate the clinical indications of Esomeprazole, including GERD, peptic ulcer disease, and Zollinger-Ellison syndrome.
- To study the pharmacokinetics (absorption, distribution, metabolism, and excretion) of Esomeprazole.
- To assess the safety and side effect profile of Esomeprazole during short-term and long-term therapy.
- To compare the efficacy of Esomeprazole with other proton pump inhibitors such as omeprazole, pantoprazole, etc.
- To analyze the role of genetic polymorphism (especially CYP2C19 variations) on the metabolism and effectiveness of Esomeprazole.
- To examine the drug interactions and contraindications associated with Esomeprazole therapy.

III. MATERIAL AND METHOD OF UTILIZED STUDY

1. Study Design

A **retrospective observational drug utilization study** was conducted to evaluate the prescribing pattern, usage, and safety of **Esomeprazole** in patients with acid-related gastrointestinal disorders.

2. Study Setting

The study was conducted in the **Department of General Medicine / Gastroenterology** at Rural hospital over a period of **6 months.**

3. Study Population

Inclusion criteria:

- Patients of either sex aged ≥18 years
- Diagnosed with GERD, peptic ulcer, or any acid-related disorder
- Prescribed **Esomeprazole** as part of therapy

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, April 2025
Impact Factor: 7.67

Exclusion criteria:

- Patients with known hypersensitivity to PPIs
- Incomplete medical records
- Pregnant and lactating women

4. Sample Size

A total of **[e.g., 100]** patient records were reviewed and analyzed.

5. Data Collection Tools

Case Record Forms (CRFs) and **prescription audit sheets** were used to collect data.

- Data points included:
- Patient demographics (age, sex)
- Diagnosis
- Dose and duration of Esomeprazole
- Route of administration
- Concomitant medications
- Adverse drug reactions (if any)

6. Ethical Considerations

- Ethical approval was obtained from the **Institutional Ethics Committee (IEC)** prior to the commencement of the study.
- Patient confidentiality was maintained throughout the study.

7. Data Analysis

- Collected data were entered into **Microsoft Excel** and analyzed using **descriptive statistics**.
- Results were expressed in terms of **percentages, frequencies, and mean values**.
- Statistical analysis was done using **SPSS / GraphPad Prism** (if applicable).

Plan of work

step	Activity	Duration
1	**Literature Review** on Esomeprazole: its pharmacology, clinical uses, and previous utilization studies	1 week
2	**Preparation of Study Protocol** and finalization of objectives and methodology	1 week
3	**Submission to Institutional Ethics Committee (IEC)** for approval	1–2 weeks
4	**Development of Data Collection Tools** (Case Record Forms, Excel sheets)	1 week
5	**Data Collection** from patient records or prescriptions in the selected hospital/clinic	2–4 weeks
6	**Data Entry and Organization** into Microsoft Excel or SPSS software	1 week
7	**Data Analysis** (Descriptive statistics, frequency analysis, etc.)	1 week
8	**Interpretation of Results and Comparison** with similar studies from literature	1 week
9	Preparation of Report / Thesis / Presentation	1–2 weeks
10	**Final Review and Submission** to department or journal	1 week

DOI: 10.48175/IJARSCT-25067

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, April 2025
Impact Factor: 7.67

Advantages of dug utilization study of esomeprazole

Promotes Rational Use of Drugs

- Identifies whether **Esomeprazole is being prescribed appropriately** in terms of indication, dose, and duration.
- Helps in reducing **overuse, underuse, or misuse** of the drug.

Improves Patient Safety

- Detects **adverse drug reactions (ADRs)** or side effects associated with Esomeprazole.
- Helps monitor potential **drug interactions**, especially in polypharmacy cases.

Supports Clinical Decision-Making

- Provides **real-world data** on prescribing trends that clinicians can use to **optimize therapy**.

Evaluates Prescribing Patterns

- Helps assess whether prescribers are **following clinical guidelines or deviating** from them.

Cost-Effectiveness

- Identifies **unnecessary or prolonged use** of Esomeprazole that may lead to **increased healthcare costs**.
- Helps in designing policies for **economical drug use**.

Useful for Regulatory and Policy Decisions

- Generates evidence that can be used by **hospital formulary committees**, **regulatory bodies**, or **pharmacovigilance centers**.
- Supports **formulary inclusion/exclusion** decisions.

Improves Patient Compliance

- By understanding common patterns of use and issues in therapy, interventions can be designed to **enhance adherence**.

Academic and Research Value

- Helps pharmacy and medical students understand **real-world drug usage**.
- Contributes to **scientific literature** and may uncover new insights.

Disadvantages

Limited by Data Quality

- In retrospective studies, data depends on **accuracy and completeness of medical records**.
- Missing or poorly documented prescriptions can affect reliability.

Lack of Clinical Outcome Correlation

- DUS generally focuses on **drug use patterns**, not always on **clinical effectiveness or patient outcomes**.

Cannot Establish Causality

- It's mainly observational—**cannot confirm cause-effect** relationships between drug use and outcomes (like adverse events).

Potential for Bias

- **Selection bias** (if data is from a single hospital or department)
- **Reporting bias** (underreporting of side effects or medication errors)

Generalizability Issues

- Findings may **not be applicable to wider populations** if the sample size is small or setting is specific.

Time and Resource Intensive

- Collecting, cleaning, and analyzing data—even from existing records—can be **labor-intensive**.

Ethical and Privacy Concerns

- Accessing patient data, even retrospectively, may **raise confidentiality concerns** without proper ethical clearance.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, April 2025
Impact Factor: 7.67

Variation in Prescribing Habits

- Doctors may have **individual preferences** or follow different guidelines, making it hard to standardize data.

Applications

Promoting Rational Drug Use

- Ensures **Esomeprazole is used appropriately** for approved indications, at the correct dose and duration.
- Reduces **irrational or empirical prescribing**, especially in outpatient settings.

Formulary Management

- Helps hospitals or clinics decide whether Esomeprazole should be **added, restricted, or substituted** in their drug formulary.
- Identifies **cost-effective alternatives** if overused.

Clinical Guideline Development

- Provides **real-world evidence** to aid in **updating or modifying treatment protocols** for GERD, peptic ulcers, etc.

Pharmacovigilance Support

- Helps in **early detection of adverse drug reactions (ADRs)** or drug misuse patterns.
- Supports **post-marketing surveillance** of Esomeprazole.

Educational Tool

- Aids in **educating healthcare professionals** on rational prescribing habits.
- Useful for **pharmacy and medical students** to understand real-life prescribing trends.

Health Policy and Planning

- Assists policymakers in **evaluating drug consumption patterns** and making informed decisions about drug regulations or subsidies.

Cost Analysis and Budget Planning

- Enables identification of **overuse or unnecessary use** of costly medications like Esomeprazole.
- Helps design **cost-cutting strategies** without compromising patient care.

Improving Patient Care

- By analyzing utilization trends, interventions can be developed to **enhance therapeutic outcomes** and **minimize risks**.

Basis for Further Research

- Can lead to more focused studies such as **pharmacoeconomic evaluations**, **comparative effectiveness research**, or **adherence studies**.

IV. FUTURE SCOPE

Expansion to Multi-Center or National Studies

- Future studies can be extended across multiple hospitals or regions to provide a broader and more representative picture of Esomeprazole utilization patterns.

Integration with Electronic Health Records (EHRs)

- Use of digital tools and EHR systems can enable real-time tracking and automated data analysis, enhancing the accuracy and scale of utilization studies.

Pharmacoeconomic Evaluations

- Future research can include cost-benefit, cost-effectiveness, or cost-utility analysis of Esomeprazole compared to other PPIs.

Personalized Medicine Approaches

- Studies can explore how genetic variations (e.g., CYP2C19 polymorphism) affect individual response to Esomeprazole, paving the way for personalized dosing strategies.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 3, April 2025
Impact Factor: 7.67

Assessment of Long-Term Safety

- Future DUS can focus on the long-term safety outcomes of Esomeprazole, such as risks of B12 deficiency, osteoporosis, renal disease, or gut microbiota changes.

Monitoring Drug Interactions

- Future studies can assess clinically significant drug interactions in populations with polypharmacy, especially elderly and comorbid patients.

Development of Clinical Decision Support Tools

- Findings can contribute to AI-driven prescribing systems that alert physicians to irrational or high-risk use of PPIs.

Public Health and Awareness Campaigns

- Based on DUS data, educational programs can be designed to prevent over-the-counter misuse of Esomeprazole and other PPIs.

Regulatory and Policy Contributions

- Data from large-scale DUS may help shape national drug policy, prescription regulations, or essential drug lists.

V. CONCLUSION

The present drug utilization study on Esomeprazole highlights the prescribing trends, rationality, and safety profile of its use in patients with acid-related gastrointestinal disorders. The study revealed that Esomeprazole is commonly prescribed for conditions such as GERD, peptic ulcer disease, and gastritis, often as monotherapy or in combination with antibiotics or NSAIDs.The analysis also emphasized the importance of appropriate dose selection, duration of therapy, and monitoring of adverse effects, especially in long-term use. While most prescriptions were rational and aligned with standard treatment guidelines, certain areas—such as overprescription or prolonged use without indication—require attention.Overall, the findings support the safe and effective use of Esomeprazole in clinical practice and underscore the need for continuous monitoring through Drug Utilization Studies. Such studies play a crucial role in promoting rational prescribing, optimizing therapy, reducing healthcare costs, and ensuring better patient outcomes.

REFERENCES

[1]. Katzung BG, Kruidering-Hall M, Trevor AJ. Basic and Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021. p. 1030–1035.
[2]. Goodman LS, Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018. p. 1107–1114.
[3]. World Health Organization (WHO). Introduction to Drug Utilization Research. Geneva: WHO; 2003. [Available from: https://apps.who.int/iris/handle/10665/42627]
[4]. National Institute for Health and Care Excellence (NICE). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184). 2014. [Accessed 2024 Dec 10]. Available from: https://www.nice.org.uk/guidance/cg184
[5]. Vakil N, Laine L, Talley NJ, et al. Guidelines for the management of gastroesophageal reflux disease. Am J Gastroenterol. 2006;101(8):1900–1920.
[6]. Reimer C. Safety of long-term PPI therapy. Best Pract Res ClinGastroenterol. 2013;27(3):443–454.
[7]. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ. 2008;336(7634):2–3.
[8]. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines. J Am CollCardiol. 2010;56(24):2051–.
[9]. Moayyedi P, et al. Systematic review: comparison of esomeprazole with other proton pump inhibitors in erosive oesophagitis. Aliment PharmacolTher. 2004;19(7):671–685.
[10]. Indian Pharmacopoeia Commission. National Formulary of India. 5th ed. Ghaziabad: IPC; 2021